Forefront is the complimentary magazine of the Mayo Clinic Cancer Center. Published in email and online newsletter editions quarterly, Forefront highlights Mayo Clinic’s cutting-edge cancer research and the latest Cancer Center news.

The September 2019 issue features:

• Director’s message: Recognition for a job well done
  After a rigorous review, NCI has renewed Mayo Clinic Cancer Center's elite designation and grant funding.

• Treatment of smoldering myeloma delays progression, study finds
  Use of the drug lenalidomide instead of observation can delay symptom progression and organ damage.

• Discrimination, gender bias toward health care staff common
  Cancer doctors face racism and gender disparity from both patients and colleagues, studies find.

• Breast cancer risk score buoys preventive medication use
  A study that may change practice shows personal risk scores can encourage women to accept treatment.

• Researchers test electronic nose to screen for Barrett's esophagus
  A novel e-nose showed high accuracy, especially for patients taking high-dose proton pump inhibitors.

• Less-invasive mastectomy safe option for more breast cancer patients
  Even women with locally advanced cancer or at risk of complications could have nipple-sparing surgery.

• 3 factors may extend survival in advanced pancreatic cancer
  A different approach to chemotherapy before surgery and radiation boosted average survival to 58.8 months.

• Meet the investigator: Donald W. Northfelt, M.D.
  In this Cancer Center video, Dr. Northfelt discusses breast cancer and equity in clinical trials.

Stay connected to Mayo Clinic Cancer Center

• View the online edition of Forefront.
• View the email newsletter.
• Subscribe to Forefront.

###

Tags: Barrett's esophagus, breast cancer, chemotherapy, Donald Northfelt, Forefront, Mayo Clinic Cancer Center, myeloma, National Cancer Institute, News, pancreatic cancer